Sort
21,281 grants matching “influenza”
Visualizing Effects of Costimulation on Antiviral Immunity
$431,142Arlene H Sharpe · Harvard Medical School · P01 · FY2008 · AI
A Multi-Ethnic Faith and Public Health Partnership to Reduce Health Disparities
$430,982Kathryn Pitkin Derose · Rand Corporation · R24 · FY2014 · MD
Synthesis of Lipooligosaccharide-Capsular Polysaccharide Conjugates for the Prevention and Treatment of Infections Caused by Acinetobacter baumannii
$430,960Justin Robert Ragains · Louisiana State Univ A&M Col Baton Rouge · R15 · FY2019 · AI
Characterization of Cellular Proteins Involved in HIV Infection
$430,933William Austin O'Brien · Zirus, Inc. · R43 · FY2009 · AI
Structural Biology and Inhibition of MDR ABC Transporters
$430,866Geoffrey A Chang · Scripps Research Institute, The · R01 · FY2007 · GM
Role of RNA helicase DDX1 in influenza A virus replication
$430,721Yuchun Du · University Of Arkansas At Fayetteville · R15 · FY2022 · AI
The Role of Phosphoinositides in Influenza Virus Assembly
$430,613Samuel T Hess · University Of Maine Orono · R15 · FY2024 · GM
T CELL RESPONSE OF ELDERLY TO INFLUENZA IMMUNIZATION
$430,592Mcp Hahnemann University · R01 · FY2000 · AG
Translational Control in Influenza Virus Infected Cells
$430,440University Of Washington · R01 · FY2005 · AI
Characterization of Biofilms by Correlated Mass Spectrometric and Raman Imaging
$430,230Joshua Shrout · University Of Notre Dame · R01 · FY2017 · AI
Modeling viral entry and its inhibition using SARS-CoV
$430,078Graham Simmons · Vitalant · R01 · FY2010 · AI
HIV infection and innate defense mechanisms in dendritic cells
$430,023Ana Fernandez-Sesma · Salk Institute For Biological Studies · P01 · FY2013 · AI
microRNA Regulation of T Cell Senescence
$429,942Jorg J Goronzy · Palo Alto Veterans Instit For Research · R01 · FY2014 · AI
Alveolar type II cell innate immune response to influenza
$429,913Robert James Mason · National Jewish Health · U01 · FY2009 · AI
Physical Activity, Aging and Immune Function
$429,891University Of Illinois Urbana-Champaign · R01 · FY2003 · AG
DEPRESSION AND TRIAL OF VARICELLA VACCINE IN THE ELDERLY
$429,865University Of California Los Angeles · R01 · FY2002 · MH
microRNA Regulation of T Cell Senescence
$429,864Jorg J Goronzy · Palo Alto Veterans Instit For Research · R01 · FY2015 · AI
microRNA Regulation of T Cell Senescence
$429,864Jorg J Goronzy · Palo Alto Veterans Instit For Research · R01 · FY2016 · AI
microRNA Regulation of T Cell Senescence
$429,864Jorg J Goronzy · Palo Alto Veterans Instit For Research · R01 · FY2017 · AI
Specialized Pro-Resolving Mediators in Asthma
$429,790Bruce D Levy · Brigham And Women'S Hospital · R01 · FY2017 · HL
Specialized Pro-Resolving Mediators in Asthma
$429,790Bruce D Levy · Brigham And Women'S Hospital · R01 · FY2016 · HL
Quorum Sensing in H. influenzae otitis
$429,750Seattle Biomedical Research Institute · R01 · FY2005 · DC
Quorum Sensing in H. influenzae otitis
$429,750Seattle Biomedical Research Institute · R01 · FY2004 · DC
VACCINES ARE THE MOST EFFECTIVE STRATEGY FOR PREVENTION AND CONTROL OF LIVESTOCK INFECTIOUS DISEASES, AND VIRAL VECTORS ARE AMONGTHE MOST PROMISING PLATFORMS TO ADMINISTER THE NEXT-GENERATION OF VETERINARY VACCINES. VIRAL VACCINE DELIVERY SYSTEMS THAT HAVEBEEN DEVELOPED AND ARE CURRENTLY IN USE IN VETERINARY MEDICINE, INCLUDE POXVIRUSES, HERPESVIRUSES, ALPHAVIRUSES ANDPARAMYXOVIRUSES. THEIR EFFECTIVENESS IS BASED ON THE ABILITY OF THE VECTOR TO INDUCE BOTH ARMS OF THE IMMUNE SYSTEM RESULTING INTHE PRODUCTION OF ANTIBODIES AND CELLULAR CELLULAR IMMUNE RESPONSES IN TARGET ANIMAL SPECIES. ADDITIONALLY, VECTORED VACCINES AREUSUALLY SAFER THAN MODIFIED LIVE VACCINES, AND MOST VIRAL VECTORS OFFER A FLEXIBLE PLATFORM THAT CAN BE RAPIDLY ENGINEERED INTONOVEL VACCINE CANDIDATES.THE GOAL OF THE STUDY PROPOSED HERE IS TO DEVELOP A MULTI-SPECIES VECTOR PLATFORM FOR VACCINE DELIVERY IN CATTLE AND SWINE.SPECIFIC AIMS OF THE STUDY ARE: 1) TO DEVELOP AN ORFV-BASED VECTOR PLATFORM WITH ENHANCED IMMUNOGENICITY AND SAFETY,2) TO CONSTRUCT RECOMBINANT ORFV VECTORS EXPRESSING PROTECTIVE ANTIGENS OF IMPORTANT PATHOGENS OF CATTLE AND SWINE,AND 3) TO EVALUATE THE IMMUNOGENICITY AND PROTECTIVE EFFICACY OF ORFV-BASED RECOMBINANT VECTORS IN TARGET ANIMALSPECIES. A NOVEL VECTOR PLATFORM BASED ON THE RECENTLY CHARACTERIZED AND HIGHLY IMMUNOGENIC PARAPOXVIRUS ORF VIRUS WILL BEDEVELOPED HERE. BY USING TRADITIONAL VIRAL GENETIC ENGINEERINF APPROACHES A GENE THAT CONTRIBUTES TO THE PATHOGENICITY OF ORFVWILL BE REMOVED FROM THE ORFV GENOME. THIS PLATFORM WILL BE USED TO GENERATE RECOMBINANT VECTORS EXPRESSING THE PROTECTIVEANTIGENS OF IMPORTANT VIRAL PATHOGENS OF CATTLE (BOVINE HERPESVIRUS 1, BOHV-1) AND SWINE (SWINE INFLUENZA VIRUS, SIV). ADDITIONALEXPERIMENTAL APPROACHES WILL INCLUDE EVALUATION OF THE IMMUNOGENICITY AND PROTECTIVE EFFICACY OF THE ORFV VECTOR PLATFORMFOLLOWING IMMUNIZATION-CHALLENGE EXPERIMENTS IN TARGET ANIMAL SPECIES. SEROLOGICAL AND CELL MEDIATED IMMUNE RESPONSESELICITED BY IMMUNIZATION WITH ORFV VECTORS WILL BE ASSESSED BY QUANTIFYING ANTIGEN/VIRUS SPECIFIC ANTIBODY LEVELS CELL EFFECTORAND MEMORY RESPONSES BY FLOW CYTOMETRY, RESPECTIVELY.THE PROPOSED WORK WILL HAVE A SIGNIFICANT IMPACT ON ANIMAL HEALTH BY PROVIDING A SAFE AND HIGHLY IMMUNOGENIC VACCINE DELIVERYPLATFORM FOR INFECTIOUS DISEASE PREVENTION AND CONTROL IN LIVESTOCK SPECIES. AVAILABILITY OF A MULTI-SPECIES VACCINE DELIVERYPLATFORM THAT ALLOWS RAPID GENERATION OF NOVEL VECTORED VACCINE CANDIDATES MAY BE HIGHLY EFFECTIVE TO COMBAT ENDEMIC, NEWLY- ORRE-EMERGING INFECTIOUS DISEASES THAT CURRENTLY THREATEN OR MAY BECOME A THREAT TO THE US LIVESTOCK INDUSTRY.
$429,739Cornell University · · FY2020 · National Institute of Food and Agriculture
Identification of rare variants that disrupt signaling pathways and networks inv
$429,669Steven M Wolinsky · Icahn School Of Medicine At Mount Sinai · U19 · FY2015 · AI